XENE - ゼノン・ファ―マシュ―ティカルズ (Xenon Pharmaceuticals Inc.) ゼノン・ファ―マシュ―ティカルズ

 XENEのチャート


 XENEの企業情報

symbol XENE
会社名 Xenon Pharmaceuticals Inc (ゼノン・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera TV-45070 GDC-0310 XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101 is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.   ゼノン・ファ―マシュ―ティカルズはカナダのバイオ医薬品会社。同社は希少疾患に対する医薬品の開発に従事する。リポタンパクリバ―ゼ欠損症、帯状疱疹後神経痛、ドラベ症候群(難治性てんかん)、炎症性痛、神経障害痛などイオンチャネルの変異による疾患向け治療薬の臨床段階の治験を行う。本社はブリティッシュコロンビア州バ―ナビ―。   Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
本社所在地 200-3650 Gilmore Way Burnaby British Columbia V5G 4W8 CAN
代表者氏名 Michael M. Tarnow Michael M. Tarnow
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 604-484-3300
設立年月日 35370
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 81人
url www.xenon-pharma.com
nasdaq_url https://www.nasdaq.com/symbol/xene
adr_tso
EBITDA EBITDA(百万ドル) -31.48200
終値(lastsale) 10.8901
時価総額(marketcap) 223921027.3989
時価総額 時価総額(百万ドル) 262.84410
売上高 売上高(百万ドル) 0.28000
企業価値(EV) 企業価値(EV)(百万ドル) 233.12010
当期純利益 当期純利益(百万ドル) -26.36700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Xenon Pharmaceuticals Inc revenues decreased from $31K to $0K. Net loss applicable to common stockholders decreased 29% to $10.6M. Revenues reflect Collaboration revenue decrease from $30K to $0K. Lower net loss reflects Research and development decrease of 9% to $11M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.83 to -$0.72.

 XENEのテクニカル分析


 XENEのニュース

   Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference  2022/06/01 20:01:00 GlobeNewswire
BURNABY, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference to be held June 8-10, 2022 in New York, NY.
   Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Could Be Worth Considering  2022/05/28 12:00:00 Stocks Register
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) price on Friday, May 27, rose 3.58% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $27.49. A look at the stock’s price movement, the close in the last trading session was $26.54, moving within a range at $26.12 and $27.86. The beta value … Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Could Be Worth Considering Read More »
   Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update  2022/05/10 20:01:00 GlobeNewswire
XEN1101 “End of Phase 2” Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022
   Xenon Pharmaceuticals Q1 Earnings Preview  2022/05/09 21:35:55 Seeking Alpha
Xenon Pharmaceuticals (XENE) is scheduled to announce Q1 earnings results on Tuesday, May 10, after market close.The consensus EPS estimate is -$0.40 and the consensus revenue estimate…
   Xenon Pharmaceuticals Inc. (XENE): Is It Worth A Small Bite At $27.23?  2022/05/07 15:30:00 Stocks Register
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) price on Friday, May 06, fall -3.68% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $27.23. A look at the stock’s price movement, the close in the last trading session was $28.27, moving within a range at $26.16 and $27.85. The beta value … Xenon Pharmaceuticals Inc. (XENE): Is It Worth A Small Bite At $27.23? Read More »
   Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update  2022/03/01 21:01:00 GlobeNewswire
Conference Call at 4:30 pm ET Today Conference Call at 4:30 pm ET Today
   Xenon draws buyout speculation after Zogenix deal  2022/01/19 15:51:29 Seeking Alpha
Dealreporter flags Xenon Pharmaceuticals <> as a potential acquisition target following the agreement between Zogenix <> and UCB under which the Belgian drugmaker offered
   Xenon passes regulatory mark to receive $15M from Neurocrine Biosciences  2022/01/12 13:22:08 Seeking Alpha
Xenon Pharmaceuticals (XENE) reaches regulatory milestone to receive a payment of $15M from Neurocrine Biosciences (NBIX) under its collaboration to develop treatments for epilepsy. It
   Sizing Up Xenon Pharmaceuticals  2021/12/13 17:10:33 Seeking Alpha
   Brokerages Anticipate Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Will Post Earnings of -$0.42 Per Share  2021/12/12 16:06:42 Transcript Daily
Brokerages expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to announce earnings of ($0.42) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Xenon Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.67). Xenon Pharmaceuticals reported earnings of ($0.34) per []
   Xenon Pharmaceuticals (XENE) Investor Presentation - Slideshow  2021/12/06 17:38:47 Seeking Alpha
   Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b X-TOLE Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)  2021/12/03 12:00:00 Intrado Digital Media
Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups
   Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2021)  2021/12/03 11:55:00 Intrado Digital Media
BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2021).
   Analysts Anticipate Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Will Announce Quarterly Sales of $7.10 Million  2021/11/27 18:30:42 Transcript Daily
Equities analysts forecast that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will post $7.10 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Xenon Pharmaceuticals earnings, with estimates ranging from $4.00 million to $8.80 million. Xenon Pharmaceuticals posted sales of $5.15 million in the same quarter last year, which would []
   -$0.42 Earnings Per Share Expected for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) This Quarter  2021/11/27 18:30:41 Dakota Financial News
Analysts expect that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will report earnings of ($0.42) per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Xenon Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.67) and the highest estimate coming in at ($0.29). Xenon Pharmaceuticals posted earnings per share of []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ゼノン・ファ―マシュ―ティカルズ XENE Xenon Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)